Hims & Hers Health (NYSE:HIMS) Trading Up 4%

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price was up 4% during mid-day trading on Monday . The company traded as high as $21.14 and last traded at $20.99. Approximately 3,239,400 shares were traded during trading, a decline of 57% from the average daily volume of 7,469,176 shares. The stock had previously closed at $20.19.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HIMS shares. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Jefferies Financial Group boosted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. Finally, Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Hims & Hers Health Stock Performance

The company’s fifty day moving average is $17.59 and its 200-day moving average is $13.55. The company has a market capitalization of $4.51 billion, a PE ratio of -2,099.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same period in the prior year, the company posted ($0.05) EPS. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 11,546 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $22.21, for a total transaction of $256,436.66. Following the completion of the transaction, the chief financial officer now directly owns 177,449 shares in the company, valued at approximately $3,941,142.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,546 shares of Hims & Hers Health stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66. Following the completion of the transaction, the chief financial officer now directly owns 177,449 shares of the company’s stock, valued at $3,941,142.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The disclosure for this sale can be found here. Insiders sold 960,288 shares of company stock worth $16,891,553 in the last three months. 17.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of large investors have recently made changes to their positions in HIMS. Belpointe Asset Management LLC raised its holdings in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after acquiring an additional 1,205 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Hims & Hers Health by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after acquiring an additional 1,561 shares in the last quarter. Swiss National Bank raised its holdings in shares of Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after acquiring an additional 2,000 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Hims & Hers Health by 10.0% in the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after acquiring an additional 2,023 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Hims & Hers Health by 17.9% in the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after acquiring an additional 2,525 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.